Brief: Cara Therapeutics Presents Late-Breaking Results Of The Komfort Phase 2 Trial Of Oral Difelikefalin For Pruritus In Notalgia Paresthetica At 31St EADV Congress

Tvardi Therapeutics

08/09/2022 13:17

Sept 8 (Reuters) - Cara Therapeutics Inc  CARA.O :
    * CARA THERAPEUTICS PRESENTS LATE-BREAKING RESULTS OF THE
KOMFORT
PHASE 2 TRIAL OF ORAL DIFELIKEFALIN FOR PRURITUS IN NOTALGIA
PARESTHETICA AT THE 31ST EADV CONGRESS
    * CARA THERAPEUTICS INC - SIGNIFICANT REDUCTION OF ITCH
INTENSITY
WAS EVIDENT AT DAY 1 AND EFFECT WAS MAINTAINED THROUGH WEEK 8
    * CARA THERAPEUTICS INC - SIGNIFICANTLY GREATER PROPORTION
OF
PATIENTS WHO RECEIVED ORAL DIFELIKEFALIN
    * CARA THERAPEUTICS INC - ORAL DIFELIKEFALIN WAS GENERALLY
WELL
TOLERATED
    * CARA THERAPEUTICS INC - ADVERSE EVENTS IN
DIFELIKEFALIN-TREATED
PATIENTS REPORTED AS MILD OR MODERATE IN SEVERITY

Source text for Eikon:  ID:nGNX4Ckmt8 
Further company coverage:  CARA.O 

 ((Reuters.Briefs@thomsonreuters.com;))